Carlos V. Paya M.D., Ph.D.

Dr. Paya was the president, chief executive officer and board member of Immune Design Corp., a late-stage immunotherapy company, from May 2011 until its acquisition by Merck & Co., Inc. in April 2019. He previously served as president of Elan Pharmaceuticals, and spent a number of years with Eli Lilly and Co.